It is also possible that tumor ablation in the melanoma xenograft model may be less dependent on PKC activation and more reliant on alternate targets, potentially including but not limited to those proteins containing a C1 domain for this group of natural epoxytiglianes and analogues. The gene discussed is PRRT2; the disease is melanoma.